Autoinjectors Global Market Report 2024

An autoinjector is a device designed for self-administering a single, predetermined dose of medication into the body. Typically, it features a spring-loaded syringe that is activated upon firm pressure against the body.

The primary types of autoinjectors are disposable autoinjectors and reusable autoinjectors. The market for disposable autoinjectors involves the sales of devices designed to replace traditional pre-filled syringes, aiming to eliminate psychological barriers by concealing the needle from the patient's view. These autoinjectors integrate a spring-powered mechanism with a shielded needle for subcutaneous or intramuscular administration of the required drug solution. They find application in various therapies such as rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and others, administered through routes like subcutaneous and intramuscular. Distribution channels include online retailers and pharmacies, and they are utilized in diverse settings, including home care, hospitals, clinics, and others.

The autoinjectors market research report is one of a series of new reports that provides autoinjectors market statistics, including autoinjectors industry global market size, regional shares, competitors with an market share, detailed autoinjectors market segments, market trends and opportunities, and any further data you may need to thrive in the autoinjectors industry. This autoinjectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The autoinjectors market size has grown exponentially in recent years. It will grow from $3.06 billion in 2023 to $3.79 billion in 2024 at a compound annual growth rate (CAGR) of 23.6%. The growth in the historic period can be attributed to factors such as the increased prevalence of chronic diseases, a growing aging population, the rise in the biotechnology and pharmaceutical sector, an increase in patient preference for self-administration, and regulatory support.

The autoinjectors market size is expected to see exponential growth in the next few years. It will grow to $8.37 billion in 2028 at a compound annual growth rate (CAGR) of 21.9%. The anticipated growth in the forecast period can be attributed to factors such as the expansion of therapeutic applications, the rise in healthcare costs, an increased focus on patient-centered care, the adoption of telemedicine and remote patient monitoring, and opportunities in emerging markets. Key trends expected in this period include the development of personalized drug delivery solutions, the emergence of connected and smart autoinjectors, the exploration of needle-free autoinjectors, advancements in biologic drug delivery, and the incorporation of safety and security features in autoinjector technologies.

The increasing prevalence of chronic diseases is poised to drive the growth of the autoinjectors market in the coming years. Chronic diseases are defined as long-lasting illnesses requiring ongoing medical attention. Conditions like heart disease, cancer, rheumatoid arthritis, and diabetes are among the leading causes of death and disability worldwide. Autoinjectors are designed for administering multiple injections of biologics and hormones to patients who need regular, long-term treatment for medical conditions like diabetes and rheumatoid arthritis. For example, a 2020 study conducted by Imperial College London estimated that chronic diseases are expected to cause nearly 41 million deaths globally each year, accounting for seven out of ten fatalities. Approximately 17 million of these deaths are considered premature, with people dying at a younger age than expected, on average. Therefore, the increasing prevalence of chronic diseases is a significant driver for the growth of the autoinjectors market.

Rising healthcare expenditure is anticipated to boost the autoinjectors market. Healthcare expenditure refers to the total amount of money spent on healthcare services, goods, and activities within a specific healthcare system or economy over a defined period. Increased healthcare expenditure supports the development, affordability, and accessibility of autoinjectors for patients. Moreover, greater demand for autoinjectors can drive innovation in the field of autoinjector development. As an illustration, according to a report published by the UK's Office for National Statistics in May 2023, healthcare spending in the UK increased by 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021. In 2021, total healthcare expenditure in the UK reached $367.25 billion (£280.7 billion), with pharmaceutical expenditure at $51.84 billion (£39.6 billion), and spending on preventive care more than doubling from 2020, totaling $45.93 billion (£35.1 billion). Thus, rising healthcare expenditures are playing a significant role in propelling the autoinjectors market.

Technological advancements are shaping the autoinjectors market. Major players in the autoinjector sector are actively working on technological solutions to meet the demand for more effective delivery mechanisms for viscous biologics. For instance, in February 2021, Becton Dickinson (BD), a US-based medical device company, is developing the Intevia 2.25 mL autoinjector based on thinner wall cannula technology. The Intevia 2.25 mL is designed to provide a patient-centric device that seamlessly works with BD Neopak XtraFlow prefillable syringes and features an 8-millimeter needle with a thinner wall for improved functionality. This illustrates how technological advancements are driving innovation within the autoinjectors market.

Major companies in the auto-injectors market are focused on developing innovative products to address the growing demand for sustainable drug delivery devices while offering more cost-effective solutions for self-administered drug delivery. One such innovative product is the Qfinity auto-injector platform, designed to be both sustainable and affordable. The platform incorporates durable materials capable of withstanding over 100 injections and features a pre-filled disposable cassette system that minimizes waste. For example, in May 2022, Jabil Inc., a US-based healthcare manufacturing company, introduced the Qfinity auto-injector platform. This platform is a straightforward, reusable, and modular solution for self-administering subcutaneous (SC) drugs, including larger-volume and higher-viscosity medicines. It offers sustainability, cost-effectiveness, versatility, ease of use, accuracy, safety, portability, and durability for self-administered drug delivery.

In April 2022, Halozyme Therapeutics Inc., a US-based biotechnology company, acquired Antares Pharma Inc. for $960 million. This strategic acquisition is aimed at expanding Halozyme Therapeutics Inc.'s portfolio of drug delivery technologies and gaining access to Antares' commercial infrastructure. The acquisition positions them to become a leading company in the field of drug delivery. Antares Pharma Inc. is a US-based pharmaceutical product development company specializing in the development of auto-injectors. This acquisition will likely enhance Halozyme's capabilities in delivering innovative drug delivery solutions, including auto-injectors, to a broader market.

Major companies operating in the autoinjectors market include AbbVie Inc., Mylan N.V., Eli Lilly and Company, Amgen Inc., Becton, Dickinson and Company, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Pfizer Inc., Bayer AG, Biogen Inc., AstraZeneca PLC, Haselmeier GmbH, Owen Mumford Ltd., Gerresheimer AG, Philip Morris International Inc., Oval Medical Technologies Ltd., Solteam Incorporation Co. Ltd., Elcam Medical Group (E3D) Ltd., Jabil Inc., Catalent Inc., SHL Medical AG, West Pharmaceutical Services Inc., Nemera Development S.A., Bespak Europe Ltd., AptarGroup Inc., Consort Medical PLC, Terumo Corporation, Nipro Corporation, Medtronic PLC, Integra LifeSciences Corporation, OssDsign AB, Xenco Medical LLC, Renishaw plc

North America was the largest region in the autoinjectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in autoinjectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the autoinjectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The autoinjectors market consists of sales of disposable and reusable autoinjectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.